Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 75Active not recruiting 68Completed 18Not yet recruiting 9Terminated 3Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, Follicular 1

Interventions

pembrolizumab 4Radiotherapy 4Radiation 4ALT-803 4fludarabine 3Prednisone 3Etoposide 3Cytarabine 3Cyclophosphamide 3Cisplatin 3Biopsy 3sacituzumab govitecan 2daratumumab 2atezolizumab 2Vincristine 2Temozolomide 2Surveys and Questionnaires 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Irinotecan 2Gemcitabine 2Doxorubicin 2Blood Specimen Collection 2Bevacizumab 2Androgen Antagonists 2130-nm albumin-bound paclitaxel 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Rituximab × 90 days × Clear all
NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡